

CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

To,
The Corporate Relationship Department
The Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

Date: January 17, 2025

Sub: Outcome of Board meeting:

REF: Sarda Proteins Limited (Scrip Code: 519242):

Dear Sir/Madam,

Please note that the meeting of the Board of Directors of the Company was held today, 17th January 2025. The Board of Directors approved the unaudited financial results for the quarter and nine months ended on 31st December 2024 along with Limited Review Report.

The copy of unaudited financial results along with Limited Review Report are attached.

The Board meeting started at 4.00 pm and was concluded at 4.40 pm.

Kindly take the same on record.

For Sarda Proteins Limited

CHIRAG
SHANTILAL
THUMAR


Digitally signed by CHIRAG
SHANTILAL THUMAR
Date: 2025.01.17 16:38:33
+05'30'

Chirag Thumar

Director

DIN: 10640822

Encl: Unaudited Financial Results



S K AGARWAL & ASSOCIATES

Chartered Accountants

111, 1st Floor, Ganpati Mall, Samtal Road, Bhiwadi-301019 (Raj.)

Mob : 9828115580 | Email : cabhiwadi@gmail.com

Limited Review Report Unaudited Standalone Quarterly Results

To
The Board of Directors
Sarda Proteins Ltd

We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter and Nine Months ended on 30th December, 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S K Agarwal & Associates
Chartered Accountants
FRN: 014841C

CA Sushil Kumar Agarwal
Partner
M. No.: 403073
UDIN : 25403073BMJODI4384
Place : Bhiwadi
Date : 17.01.2025



SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
E-Mail: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER 2024


Rs. in Lakhs

S. No.	Particulars	Quarter Ended on			Corresponding Nine Months Ended on		Year Ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I.	Revenue from Operations	2,405.10	14.00	99.99	2,419.10	123.57	129.58
II.	Other Income	0.06	-	4.21	0.06	12.43	16.53
III.	Total Income (I+II)	2,405.16	14.00	104.20	2,419.16	136.00	146.11
IV.	Expenses:						
	Cost of Material Consumed		-		-	-	-
	Purchase of Stock -in- Trade	2,391.07	-	97.07	2,391.07	120.70	120.71
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)		-		-	-	-
	Employee Benefit Expenses	1.30	1.14	3.65	6.66	9.01	14.56
	Finance Cost		-		-	-	0.01
	Depreciation and Amortisation Expenses		-		-	-	-
	Other expenses	3.08	2.39	2.79	9.26	6.36	8.95
	Total Expenses (IV)	2,395.45	3.53	103.51	2,406.99	136.07	144.23
V.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	9.71	10.47	0.69	12.17	(0.07)	1.89
VI.	Exceptional Items		-		-	-	-
VII.	Profit/(Loss) before Tax (V-VI)	9.71	10.47	0.69	12.17	(0.07)	1.89
VIII.	Tax Expense:						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	(0.05)
IX.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	9.71	10.47	0.69	12.17	(0.07)	1.94
X.	Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-
XI.	Tax Expenses of Discontinued Operations		-		-	-	-
XII.	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XIII.	Profit/(Loss) for the Period (IX+XII)	9.71	10.47	0.69	12.17	(0.07)	1.94
XIV.	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other Comprehensive Income for the period)	9.71	10.47	0.69	12.17	(0.07)	1.94
XVI.	Paid Up Equity Share Capital, Equity Shares Of Face Value Rs. 10 each	172.59	172.59	172.59	172.59	172.59	172.59
XVII.	Earnings per Equity Share						
	(1) Basic	0.56	0.61	0.04	0.71	(0.00)	0.11
	(2) Diluted	0.56	0.61	0.04	0.71	(0.00)	0.11

Notes:

1. The above results were approved by Audit Committee and Board of Directors in their meeting held on 17th January 2025.
2. Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
3. Segment Results as per AS is not applicable as dealing in only one segment i.e. "Renewable Energy Sector Solar Cell Products".
4. No Investor Complaints were received during the quarter ended 31-Dec-2024 nor any pending as on 01-Jan-2025.
5. Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.

For S K Agarwal & Associates
Chartered Accountants
FRN: 014841C


CA Sushil Kumar Agarwal
Partner
M. No.: 403073
Place: Bhiwadi
Date: 17-Jan-2025
UDIN: 25403073BMJOD14384



For and on behalf of the Board
Sarda Proteins Ltd
CIN: L15142RJ1991PLC006353

CHIRAG SHANTILAL THUMAR
Digitally signed by CHIRAG SHANTILAL THUMAR
Date: 2025.01.17 16:34:56 +05'30'

Chirag Shantilal Thumar
Managing Director
DIN: 10640822